Gene,Medication(s),Variant,rsID,Activity Score,Metabolizer Phenotype*,Implications,Recommendation**,Strength of Recommendation,PharmGKB ID
CYP2B6,Efavirenz,,,,Ultrarapid Metabolizer,Slightly lower dose-adjusted trough concentrations of efavirenz compared with normal metabolizers,Initiate efavirenz with standard dosing (600 mg/day),Strong,PA166182603
CYP2B6,Efavirenz,,,,Rapid Metabolizer,Slightly lower dose-adjusted trough concentrations of efavirenz compared with normal metabolizers,Initiate efavirenz with standard dosing (600 mg/day),Strong,PA166182603
CYP2B6,Efavirenz,,,,Normal Metabolizer,Normal efavirenz metabolism,Initiate efavirenz with standard dosing (600 mg/day),Strong,PA166182603
CYP2B6,Efavirenz,,,,Intermediate Metabolizer,Higher dose-adjusted trough concentrations of efavirenz compared with normal metabolizers; increased risk of CNS adverse events,Consider initiating efavirenz with decreased dose of 400 mg/day,Moderate,PA166182603
CYP2B6,Efavirenz,,,,Poor Metabolizer,Higher dose-adjusted trough concentrations of efavirenz compared with normal metabolizers; significantly increased risk of CNS adverse events and treatment discontinuation,Consider initiating efavirenz with decreased dose of 400 or 200 mg/day,Moderate,PA166182603
CYP2C19,Amitriptyline,,,,Ultrarapid Metabolizer,Increased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.
If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166105006
CYP2C19,Amitriptyline,,,,Rapid Metabolizer,Increased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.
If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166105006
CYP2C19,Amitriptyline,,,,Normal Metabolizer,Normal metabolism of tertiary amines,Initiate therapy with recommended starting dose,Strong,PA166105006
CYP2C19,Amitriptyline,,,,Intermediate Metabolizer,Reduced metabolism of tertiary amines compared to normal metabolizers,Initiate therapy with recommended starting dose,Strong,PA166105006
CYP2C19,Amitriptyline,,,,Poor Metabolizer,Greatly reduced metabolism of tertiary amines compared to normal metabolizers. Decreased conversion of tertiary amines to secondary amines may affect response or side effects,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.
For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments",Moderate,PA166105006
CYP2C19,"Citalopram
Escitalopram",,,,Ultrarapid Metabolizer,Increased metabolism when compared to normal metabolizers. Lower plasma concentrations will increase probability of pharmacotherapy failure,Consider an alternative drug not predominantly metabolized by CYP2C19,Moderate,PA166127638
CYP2C19,"Citalopram
Escitalopram",,,,Normal Metabolizer,Normal metabolism,Initiate therapy with recommended starting dose,Strong,PA166127638
CYP2C19,"Citalopram
Escitalopram",,,,Intermediate Metabolizer,Reduced metabolism when compared to normal metabolizers,Initiate therapy with recommended starting dose,Strong,PA166127638
CYP2C19,"Citalopram
Escitalopram",,,,Poor Metabolizer,Greatly reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects,Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19,Moderate,PA166127638
CYP2C19,Clomipramine,,,,Ultrarapid Metabolizer,Increased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.
If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166105007
CYP2C19,Clomipramine,,,,Rapid Metabolizer,Increased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.
If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166105007
CYP2C19,Clomipramine,,,,Normal Metabolizer,Normal metabolism of tertiary amines,Initiate therapy with recommended starting dose,Strong,PA166105007
CYP2C19,Clomipramine,,,,Intermediate Metabolizer,Reduced metabolism of tertiary amines compared to normal metabolizers,Initiate therapy with recommended starting dose,Optional,PA166105007
CYP2C19,Clomipramine,,,,Poor Metabolizer,Greatly reduced metabolism of tertiary amines compared to normal metabolizers. Decreased conversion of tertiary amines to secondary amines may affect response or side effects,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.
For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166105007
CYP2C19,Clopidogrel,,,,Ultrarapid Metabolizer,Increased platelet inhibition; decreased residual platelet aggregation,Clopidogrel - label recommended dosage and administration,Strong,PA166104948
CYP2C19,Clopidogrel,,,,Normal Metabolizer,Normal platelet inhibition; normal residual platelet aggregation,Clopidogrel - label recommended dosage and administration,Strong,PA166104948
CYP2C19,Clopidogrel,,,,Intermediate Metabolizer,Reduced platelet inhibition; increased residual platelet aggregation; increased risk for adverse cardiovascular events,"Alternative antiplatelet therapy (if no contraindication); e.g., prasugrel, ticagrelor",Moderate,PA166104948
CYP2C19,Clopidogrel,,,,Poor Metabolizer,Significantly reduced platelet inhibition; increased residual platelet aggregation; increased risk for adverse cardiovascular events,"Alternative antiplatelet therapy (if no contraindication); e.g., prasugrel, ticagrelor",Strong,PA166104948
CYP2C19,Dexlansoprazole,,,,Ultrarapid Metabolizer,Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure,Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy,Optional,PA166219301
CYP2C19,Dexlansoprazole,,,,Rapid Metabolizer,Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure,Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.,Optional,PA166219301
CYP2C19,Dexlansoprazole,,,,Normal Metabolizer,Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs,Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy.,Optional,PA166219301
CYP2C19,Dexlansoprazole,,,,Likely Intermediate Metabolizer,Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy",Optional,PA166219301
CYP2C19,Dexlansoprazole,,,,Intermediate Metabolizer,Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy",Optional,PA166219301
CYP2C19,Dexlansoprazole,,,,Likely Poor Metabolizer,Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity ,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",Optional,PA166219301
CYP2C19,Dexlansoprazole,,,,Poor Metabolizer,Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy",Optional,PA166219301
CYP2C19,Doxepin,,,,Ultrarapid Metabolizer,Increased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.
If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166105000
CYP2C19,Doxepin,,,,Rapid Metabolizer,Increased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.
If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166105000
CYP2C19,Doxepin,,,,Normal Metabolizer,Normal metabolism of tertiary amines,Initiate therapy with recommended starting dose,Strong,PA166105000
CYP2C19,Doxepin,,,,Intermediate Metabolizer,Reduced metabolism of tertiary amines compared to normal metabolizers,Initiate therapy with recommended starting dose,Optional,PA166105000
CYP2C19,Doxepin,,,,Poor Metabolizer,Greatly reduced metabolism of tertiary amines compared to normal metabolizers. Decreased conversion of tertiary amines to secondary amines may affect response or side effect,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.
For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166105000
CYP2C19,Imipramine,,,,Ultrarapid Metabolizer,Increased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.
If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166104999
CYP2C19,Imipramine,,,,Rapid Metabolizer,Increased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.
If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166104999
CYP2C19,Imipramine,,,,Normal Metabolizer,Normal metabolism of tertiary amines,Initiate therapy with recommended starting dose,Strong,PA166104999
CYP2C19,Imipramine,,,,Intermediate Metabolizer,Reduced metabolism of tertiary amines compared to normal metabolizers,Initiate therapy with recommended starting dose,Optional,PA166104999
CYP2C19,Imipramine,,,,Poor Metabolizer,Greatly reduced metabolism of tertiary amines compared to normal metabolizers. Decreased conversion of tertiary amines to secondary amines may affect response or side effects,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.
For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166104999
CYP2C19,"Lansoprazole
Omeprazole
Pantoprazole",,,,Ultrarapid Metabolizer,Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure,Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy,Optional,PA166219103
CYP2C19,"Lansoprazole
Omeprazole
Pantoprazole",,,,Rapid Metabolizer,Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure,Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy,Moderate,PA166219103
CYP2C19,"Lansoprazole
Omeprazole
Pantoprazole",,,,Normal Metabolizer,Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs,Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy,Moderate,PA166219103
CYP2C19,"Lansoprazole
Omeprazole
Pantoprazole",,,,Likely Intermediate Metabolizer,Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy",Optional,PA166219103
CYP2C19,"Lansoprazole
Omeprazole
Pantoprazole",,,,Intermediate Metabolizer,Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy",Optional,PA166219103
CYP2C19,"Lansoprazole
Omeprazole
Pantoprazole",,,,Likely Poor Metabolizer,Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy",Moderate,PA166219103
CYP2C19,"Lansoprazole
Omeprazole
Pantoprazole",,,,Poor Metabolizer,Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity,"Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy",Moderate,PA166219103
CYP2C19,Sertraline,,,,Ultrarapid Metabolizer,Increased metabolism when compared to normal metabolizers,"Initiate therapy with recommended starting dose. If patient does not respond to recommended maintenance dosing, consider alternative drug not predominantly metabolized by CYP2C19",Optional,PA166127639
CYP2C19,Sertraline,,,,Normal Metabolizer,Normal metabolism,Initiate therapy with recommended starting dose,Strong,PA166127639
CYP2C19,Sertraline,,,,Intermediate Metabolizer,Reduced metabolism when compared to normal metabolizers,Initiate therapy with recommended starting dose,Strong,PA166127639
CYP2C19,Sertraline,,,,Poor Metabolizer,Greatly reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects,Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19,Optional,PA166127639
CYP2C19,Trimipramine,,,,Ultrarapid Metabolizer,Increased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.
If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166105001
CYP2C19,Trimipramine,,,,Rapid Metabolizer,Increased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.
If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166105001
CYP2C19,Trimipramine,,,,Normal Metabolizer,Normal metabolism of tertiary amines,Initiate therapy with recommended starting dose,Strong,PA166105001
CYP2C19,Trimipramine,,,,Intermediate Metabolizer,Reduced metabolism of tertiary amines compared to normal metabolizers,Initiate therapy with recommended starting dose,Optional,PA166105001
CYP2C19,Trimipramine,,,,Poor Metabolizer,Greatly reduced metabolism of tertiary amines compared to normal metabolizers. Decreased conversion of tertiary amines to secondary amines may affect response or side effects,"Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.
For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166105001
CYP2C19,Voriconazole,,,,Ultrarapid Metabolizer,"In patients for whom an ultrarapid metabolizer genotype is identified, the probability of attainment of therapeutic voriconazole concentrations is small with standard dosing","Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole",Moderate,PA166161537
CYP2C19,Voriconazole,,,,Rapid Metabolizer,"In patients for whom a rapid metabolizer genotype is identified, the probability of attainment of therapeutic concentrations is modest with standard dosing","Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole",Moderate,PA166161537
CYP2C19,Voriconazole,,,,Normal Metabolizer,Normal voriconazole metabolism,Initiate therapy with recommended standard of care dosing,Strong,PA166161537
CYP2C19,Voriconazole,,,,Intermediate Metabolizer,Higher dose-adjusted trough concentrations of voriconazole compared to normal metabolizers,Initiate therapy with recommended standard of care dosing,Moderate,PA166161537
CYP2C19,Voriconazole,,,,Poor Metabolizer,Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events,"Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.f In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring",Moderate,PA166161537
CYP2C9,"Celecoxib
Flurbiprofen
Ibuprofen
Lornoxicam",,,,Normal Metabolizer,Normal metabolism,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals",Strong,PA166191841
CYP2C9,"Celecoxib
Flurbiprofen
Ibuprofen
Lornoxicam",,,1.5,Intermediate Metabolizer,Mildly reduced metabolism,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals",Moderate,PA166191841
CYP2C9,"Celecoxib
Flurbiprofen
Ibuprofen
Lornoxicam",,,1,Intermediate Metabolizer,Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities,"Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy",Moderate,PA166191841
CYP2C9,"Celecoxib
Flurbiprofen
Ibuprofen
Lornoxicam",,,,Intermediate Metabolizer,Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities,"Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy",Moderate,PA166191841
CYP2C9,"Celecoxib
Flurbiprofen
Ibuprofen
Lornoxicam",,,,Poor Metabolizer,Significantly reduced metabolism and prolonged half life; higher plasma concentrations may increase probability and/or severity of toxicities,"Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib and 5 days for ibuprofen, flurbiprofen and lornoxicam after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo",Moderate,PA166191841
CYP2C9,"Fosphenytoin
Phenytoin",,,,Normal Metabolizer,Normal phenytoin metabolism,"No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice",Strong,PA166122806
CYP2C9,"Fosphenytoin
Phenytoin",,,1.5,Intermediate Metabolizer,"Slightly reduced phenytoin metabolism; however, this does not appear to translate into increased side effects.","No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice",Moderate,PA166122806
CYP2C9,"Fosphenytoin
Phenytoin",,,1,Intermediate Metabolizer,"Reduced phenytoin metabolism, higher plasma concentrations will increase probability of toxicities","For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice",Moderate,PA166122806
CYP2C9,"Fosphenytoin
Phenytoin",,,,Intermediate Metabolizer,"Reduced phenytoin metabolism, higher plasma concentrations will increase probability of toxicities","For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice",Moderate,PA166122806
CYP2C9,"Fosphenytoin
Phenytoin",,,,Poor Metabolizer,"Reduced phenytoin metabolism, higher plasma concentrations will increase probability of toxicities","For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice",Strong,PA166122806
CYP2C9,Meloxicam,,,,Normal Metabolizer,Normal metabolism,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals",Strong,PA166192301
CYP2C9,Meloxicam,,,1.5,Intermediate Metabolizer,Mildly reduced metabolism,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals",Moderate,PA166192301
CYP2C9,Meloxicam,,,1,Intermediate Metabolizer,Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities,"Initiate therapy with 50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 50% of the maximum recommended dose with caution. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 7 days). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider alternative therapy. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life ",Moderate,PA166192301
CYP2C9,Meloxicam,,,,Intermediate Metabolizer,Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities,"Initiate therapy with 50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 50% of the maximum recommended dose with caution. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 7 days). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider alternative therapy. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life ",Moderate,PA166192301
CYP2C9,Meloxicam,,,,Poor Metabolizer,Significantly reduced metabolism and prolonged half life; higher plasma concentrations may increase probability and/or severity of toxicities,Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life ,Moderate,PA166192301
CYP2C9,Piroxicam,,,,Normal Metabolizer,Normal metabolism,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals",Strong,PA166192321
CYP2C9,Piroxicam,,,1.5,Intermediate Metabolizer,Mildly reduced metabolism,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",Moderate,PA166192321
CYP2C9,Piroxicam,,,1,Intermediate Metabolizer,Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities,Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life,Moderate,PA166192321
CYP2C9,Piroxicam,,,,Intermediate Metabolizer,Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities,Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life,Moderate,PA166192321
CYP2C9,Piroxicam,,,,Poor Metabolizer,Significantly reduced metabolism and prolonged half life; higher plasma concentrations may increase probability and/or severity of toxicities,Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life ,Moderate,PA166192321
CYP2C9,Tenoxicam,,,,Normal Metabolizer,Normal metabolism,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals",Strong,PA166192341
CYP2C9,Tenoxicam,,,1.5,Intermediate Metabolizer,Mildly reduced metabolism,"Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals",Moderate,PA166192341
CYP2C9,Tenoxicam,,,1,Intermediate Metabolizer,Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities,Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life ,Optional,PA166192341
CYP2C9,Tenoxicam,,,,Intermediate Metabolizer,Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities,Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life ,Optional,PA166192341
CYP2C9,Tenoxicam,,,,Poor Metabolizer,Significantly reduced metabolism and prolonged half life; higher plasma concentrations may increase probability and/or severity of toxicities,Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life ,Optional,PA166192341
DPYD,Capecitabine,,,,Normal Metabolizer,Normal DPD activity and normal risk for fluoropyrimidine toxicity,"Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration",Strong,PA166109594
DPYD,Capecitabine,,,1.5,Intermediate Metabolizer,Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs,Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.[2846A>T];[2846A>T] genotype may require >50% reduction in starting dose,Moderate,PA166109594
DPYD,Capecitabine,,,1,Intermediate Metabolizer,Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs,Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.[2846A>T];[2846A>T] genotype may require >50% reduction in starting dose,Strong,PA166109594
DPYD,Capecitabine,,,,Intermediate Metabolizer,Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs,Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.[2846A>T];[2846A>T] genotype may require >50% reduction in starting dose,Strong,PA166109594
DPYD,Capecitabine,,,0.5,Poor Metabolizer,Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs,"Avoid use of 5- fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose with early therapeutic drug monitoring",Strong,PA166109594
DPYD,Capecitabine,,,0,Poor Metabolizer,Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs,Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens,Strong,PA166109594
DPYD,Capecitabine,,,,Poor Metabolizer,Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs,Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens,Strong,PA166109594
DPYD,Fluorouracil,,,,Normal Metabolizer,Normal DPD activity and normal risk for fluoropyrimidine toxicity,"Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration",Strong,PA166122686
DPYD,Fluorouracil,,,1.5,Intermediate Metabolizer,Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs,Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.[2846A>T];[2846A>T] genotype may require >50% reduction in starting dose,Moderate,PA166122686
DPYD,Fluorouracil,,,1,Intermediate Metabolizer,Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs,Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.[2846A>T];[2846A>T] genotype may require >50% reduction in starting dose,Strong,PA166122686
DPYD,Fluorouracil,,,,Intermediate Metabolizer,Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs,Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.[2846A>T];[2846A>T] genotype may require >50% reduction in starting dose,Strong,PA166122686
DPYD,Fluorouracil,,,0.5,Poor Metabolizer,Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs,"Avoid use of 5- fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose with early therapeutic drug monitoring",Strong,PA166122686
DPYD,Fluorouracil,,,0,Poor Metabolizer,Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs,Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens,Strong,PA166122686
DPYD,Fluorouracil,,,,Poor Metabolizer,Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs,Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens,Strong,PA166122686
NUDT15,Azathioprine,,,,Normal Metabolizer,"Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression","Start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady state after each dose adjustment",Strong,PA166104933
NUDT15,Azathioprine,,,,Intermediate Metabolizer,"Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression","Start with reduced starting doses (30-80% of normal dose) if normal starting dose is 2-3 mg/kg/day, (e.g. 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment",Strong,PA166104933
NUDT15,Azathioprine,,,,Possible Intermediate Metabolizer,"Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression","Start with reduced starting doses (30-80% of normal dose) if normal starting dose is 2-3 mg/kg/day, (e.g. 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment",Strong,PA166104933
NUDT15,Azathioprine,,,,Poor Metabolizer,"Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression","For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment",Strong,PA166104933
NUDT15,Mercaptopurine,,,,Normal Metabolizer,"Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression","Start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment",Strong,PA166104945
NUDT15,Mercaptopurine,,,,Intermediate Metabolizer,"Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression","Start with reduced starting doses (30-80% of normal dose) if normal starting dose is > or = 75 mg/m2/day or > or = 1.5 mg/kg/day (e.g. start at 25-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already < 75 mg/m2/day or 1.5 mg/kg/day, dose reduction may not be recommended",Strong,PA166104945
NUDT15,Mercaptopurine,,,,Possible Intermediate Metabolizer,"Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression","Start with reduced starting doses (30-80% of normal dose) if normal starting dose is > or = 75 mg/m2/day or > or = 1.5 mg/kg/day (e.g. start at 25-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already < 75 mg/m2/day or 1.5 mg/kg/day, dose reduction may not be recommended",Strong,PA166104945
NUDT15,Mercaptopurine,,,,Poor Metabolizer,"Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression","For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy",Strong,PA166104945
NUDT15,Thioguanine,,,,Normal Metabolizer,"Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression",Start with normal starting dose (40-60 mg/day). Adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment,Strong,PA166104965
NUDT15,Thioguanine,,,,Intermediate Metabolizer,"Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression","Start with reduced doses (50% to 80% of normal dose) if normal starting dose is > or = 40-60 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents",Moderate,PA166104965
NUDT15,Thioguanine,,,,Possible Intermediate Metabolizer,"Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression","Start with reduced doses (50% to 80% of normal dose) if normal starting dose is > or = 40-60 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents",Moderate,PA166104965
NUDT15,Thioguanine,,,,Poor Metabolizer,"Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression","Reduce doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy",Strong,PA166104965
SLCO1B1,Simvastatin,,,,Normal Function,Normal myopathy risk,Prescribe desired starting dose and adjust doses of simvastatin based on disease-specific guidelines,Strong,PA166105005
SLCO1B1,Simvastatin,,,,Decreased Function,Intermediate myopathy risk,Prescribe a lower dose or consider an alternative statin (e.g. pravastatin or rosuvastatin); consider routine CK surveillance,Strong,PA166105005
SLCO1B1,Simvastatin,,,,Poor Function,High myopathy risk,Prescribe a lower dose or consider an alternative statin (e.g. pravastatin or rosuvastatin); consider routine CK surveillance,Strong,PA166105005
TPMT,Azathioprine,,,,Normal Metabolizer,"Lower concentrations of TGN metabolites, higher meTIMP, this is the ""normal"" pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression","Start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady state after each dose adjustment",Strong,PA166104933
TPMT,Azathioprine,,,,Intermediate Metabolizer,"Moderate to high concentrations of TGN metabolites; low concentrations of meTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression","Start with reduced starting doses (30-80% of normal dose) if normal starting dose is 2-3 mg/kg/day, (e.g. 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment",Strong,PA166104933
TPMT,Azathioprine,,,,Possible Intermediate Metabolizer,"Moderate to high concentrations of TGN metabolites; low concentrations of meTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression","Start with reduced starting doses (30-80% of normal dose) if normal starting dose is 2-3 mg/kg/day, (e.g. 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment",Strong,PA166104933
TPMT,Azathioprine,,,,Poor Metabolizer,Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no meTIMP metabolites,"For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines Allow 4-6 weeks to reach steady-state after each dose adjustment",Strong,PA166104933
TPMT,Mercaptopurine,,,,Normal Metabolizer,"Lower concentrations of TGN metabolites, higher meTIMP, this is the ""normal"" pattern. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression","Start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment",Strong,PA166104945
TPMT,Mercaptopurine,,,,Intermediate Metabolizer,"Moderate to high concentrations of TGN metabolites; low concentrations of meTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression","Start with reduced starting doses (30-80% of normal dose) if normal starting dose is > or = 75 mg/m2/day or > or = 1.5 mg/kg/day (e.g. start at 25-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended",Strong,PA166104945
TPMT,Mercaptopurine,,,,Possible Intermediate Metabolizer,"Moderate to high concentrations of TGN metabolites; low concentrations of meTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression","Start with reduced starting doses (30-80% of normal dose) if normal starting dose is > or = 75 mg/m2/day or > or = 1.5 mg/kg/day (e.g. start at 25-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended",Strong,PA166104945
TPMT,Mercaptopurine,,,,Poor Metabolizer,Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no meTIMP metabolites,"For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g. 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy",Strong,PA166104945
TPMT,Thioguanine,,,,Normal Metabolizer,"Lower concentrations of TGN metabolites, but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression",Start with normal starting dose (e.g. 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment,Strong,PA166104965
TPMT,Thioguanine,,,,Intermediate Metabolizer,"Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression","Start with reduced doses (50% to 80% of normal dose) if normal starting dose is > or = 40-60 mg/m2/day (e.g. 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents",Moderate,PA166104965
TPMT,Thioguanine,,,,Possible Intermediate Metabolizer,"Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression","Start with reduced doses (50% to 80% of normal dose) if normal starting dose is > or = 40-60 mg/m2/day (e.g. 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents",Moderate,PA166104965
TPMT,Thioguanine,,,,Poor Metabolizer,"Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease. Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression","Start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy",Strong,PA166104965
UGT1A1,Atazanavir,,,,Normal Metabolizer,Reference UGT1A1 activity; very low likelihood of bilirubin-related discontinuation of atazanavir,There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result,Strong,PA166128738
UGT1A1,Atazanavir,,,,Intermediate Metabolizer,Somewhat decreased UGT1A1 activity; low likelihood of bilirubin-related discontinuation of atazanavir,"There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient's genotype makes this unlikely",Strong,PA166128738
UGT1A1,Atazanavir,,,,Poor Metabolizer,Markedly decreased UGT1A1 activity; high likelihood of bilirubin-related discontinuation of atazanavir,Consider an alternative agent particularly where jaundice would be of concern to the patient,Strong,PA166128738
CYP2D6,Amitriptyline,,,,Ultrarapid Metabolizer,Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure,"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.
If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments",Strong,PA166105006
CYP2D6,Amitriptyline,,,,Normal Metabolizer,Normal metabolism of TCAs,Initiate therapy with recommended starting dose,Strong,PA166105006
CYP2D6,Amitriptyline,,,,Intermediate Metabolizer,Reduced metabolism of TCAs to less active compounds when compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects,Consider 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments,Moderate,PA166105006
CYP2D6,Amitriptyline,,,,Poor Metabolizer,Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects,"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.
If a TCA is warranted, consider 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments",Strong,PA166105006
CYP2D6,Atomoxetine,,,,Ultrarapid Metabolizer,"Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing","Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml",Moderate,PA166181885
CYP2D6,Atomoxetine,,,,Normal Metabolizer,Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers,"Initiate with a dose of 0.5 mg/kg and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml",Moderate,PA166181885
CYP2D6,Atomoxetine,,,1,Intermediate Metabolizer,Possibly higher atomoxetine concentrations as compared to normal metabolizers but questionable clinical significance. Normal metabolizers may be at an increased risk of increased discontinuation as compared to poor metabolizers,"Initiate with a dose of 0.5 mg/kg and increase to 1.2 mg/kg/day after 3 days If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml",Moderate,PA166181885
CYP2D6,Atomoxetine,*10,,1,Intermediate Metabolizer,Decreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Individuals with activity score of 1.0 with CYP2D6*10 may be at an increased risk of increased discontinuation as compared to poor metabolizers,"Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2-4 h after dosing. If response is inadequate and concentration is <200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml. If unacceptable side effects are presentat any time, consider a reduction in dose",Moderate,PA166181885
CYP2D6,Atomoxetine,,,0.5,Intermediate Metabolizer,Decreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Intermediate metabolizers may be at an increased risk of discontinuation as compared to poor metabolizers,"Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2-4 h after dosing. If response is inadequate and concentration is <200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml. If unacceptable side effects are present at any time, consider a reduction in dose",Moderate,PA166181885
CYP2D6,Atomoxetine,,,,Poor Metabolizer,"Significantly decreased metabolism of atomoxetine may result in higher concentrations as compared to non-poor metabolizers. This may increase the occurrence of treatment-emergent side effects, but also a greater improvement of ADHD symptoms as compared to non-poor metabolizers in those who tolerate treatment. Poor metabolizer status is associated with lower final dose requirements as compared to non-poor metabolizers","Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 4 h after dosing. If response is inadequate and concentration is <200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml. If unacceptable side effects are present at any time, consider a reduction in dose",Strong,PA166181885
CYP2D6,Clomipramine,,,,Ultrarapid Metabolizer,Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure,"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.
If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166105007
CYP2D6,Clomipramine,,,,Normal Metabolizer,Normal metabolism of TCAs,Initiate therapy with recommended starting dose,Strong,PA166105007
CYP2D6,Clomipramine,,,,Intermediate Metabolizer,Reduced metabolism of TCAs to less active compounds when compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects,Consider 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments,Optional,PA166105007
CYP2D6,Clomipramine,,,,Poor Metabolizer,Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects,"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.
If a TCA is warranted, consider 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166105007
CYP2D6,Codeine,,,,Ultrarapid Metabolizer,Increased formation of morphine leading to higher risk of toxicity,"Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid",Strong,PA166104996
CYP2D6,Codeine,,,,Normal Metabolizer,Expected morphine formation,Use codeine label recommended age- or weight-specific dosing,Strong,PA166104996
CYP2D6,Codeine,,,,Intermediate Metabolizer,Reduced morphine formation,"Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid",Moderate,PA166104996
CYP2D6,Codeine,,,,Poor Metabolizer,Greatly reduced morphine formation leading to diminished analgesia,"Avoid codeine use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-tramadol opioid",Strong,PA166104996
CYP2D6,Desipramine,,,,Ultrarapid Metabolizer,Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure,"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.
If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166105002
CYP2D6,Desipramine,,,,Normal Metabolizer,Normal metabolism of TCAs,Initiate therapy with recommended starting dose,Strong,PA166105002
CYP2D6,Desipramine,,,,Intermediate Metabolizer,Reduced metabolism of TCAs to less active compounds when compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects,Consider 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments,Optional,PA166105002
CYP2D6,Desipramine,,,,Poor Metabolizer,Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects,"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.
If a TCA is warranted, consider 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166105002
CYP2D6,Doxepin,,,,Ultrarapid Metabolizer,Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure,"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.
If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166105000
CYP2D6,Doxepin,,,,Normal Metabolizer,Normal metabolism of TCAs,Initiate therapy with recommended starting dose,Strong,PA166105000
CYP2D6,Doxepin,,,,Intermediate Metabolizer,Reduced metabolism of TCAs to less active compounds when compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects,Consider 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments,Optional,PA166105000
CYP2D6,Doxepin,,,,Poor Metabolizer,Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects,"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.
If a TCA is warranted, consider 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166105000
CYP2D6,Fluvoxamine,,,,Ultrarapid Metabolizer,No data available for CYP2D6 Ultrarapid Metabolizers,No recommendation due to lack of evidence,Optional,PA166127637
CYP2D6,Fluvoxamine,,,,Normal Metabolizer,Normal metabolism,Initiate therapy with recommended starting dose,Strong,PA166127637
CYP2D6,Fluvoxamine,,,,Intermediate Metabolizer,Reduced metabolism when compared to Normal Metabolizers. Higher plasma concentrations may increase the probability of side effects,Initiate therapy with recommended starting dose,Moderate,PA166127637
CYP2D6,Fluvoxamine,,,,Poor Metabolizer,Greatly reduced metabolism when compared to Normal Metabolizers. Higher plasma concentrations may increase the probability of side effects,Consider a 25-50% reduction of recommended starting dose and titrate to response or use an alternative drug not metabolized by CYP2D6,Optional,PA166127637
CYP2D6,Hydrocodone,,,,Ultrarapid Metabolizer,Minimal evidence for pharmacokinetic or clinical effect,No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia,No recommendation,PA166228121
CYP2D6,Hydrocodone,,,,Normal Metabolizer,Normal hydromorphone formation,Use hydrocodone label recommended age- or weight-specific dosing,Strong,PA166228121
CYP2D6,Hydrocodone,,,,Intermediate Metabolizer,Minimal evidence for pharmacokinetic or clinical effect,"Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid",Optional,PA166228121
CYP2D6,Hydrocodone,,,,Poor Metabolizer,"Decreased metabolism of hydrocodone to active metabolite hydromorphone, but there is insufficient evidence to determine if these effects on pharmacokinetics translate into decreased analgesia or side effects","Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid",Optional,PA166228121
CYP2D6,Imipramine,,,,Ultrarapid Metabolizer,Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure,"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.
If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166104999
CYP2D6,Imipramine,,,,Normal Metabolizer,Normal metabolism of TCAs,Initiate therapy with recommended starting dose,Strong,PA166104999
CYP2D6,Imipramine,,,,Intermediate Metabolizer,Reduced metabolism of TCAs to less active compounds when compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects,Consider 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments,Optional,PA166104999
CYP2D6,Imipramine,,,,Poor Metabolizer,Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects,"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.
If a TCA is warranted, consider 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166104999
CYP2D6,Nortriptyline,,,,Ultrarapid Metabolizer,Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure,"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.
If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments",Strong,PA166104998
CYP2D6,Nortriptyline,,,,Normal Metabolizer,Normal metabolism of TCAs,Initiate therapy with recommended starting dose,Strong,PA166104998
CYP2D6,Nortriptyline,,,,Intermediate Metabolizer,Reduced metabolism of TCAs to less active compounds when compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects,Consider 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments,Moderate,PA166104998
CYP2D6,Nortriptyline,,,,Poor Metabolizer,Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects,"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.
If a TCA is warranted, consider 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments",Strong,PA166104998
CYP2D6,Ondansetron,,,,Ultrarapid Metabolizer,Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting),Select and alternative drug not predominantly metabolized by CYP2D6 (i.e. granisetron),Moderate,PA166161954
CYP2D6,Ondansetron,,,,Normal Metabolizer,Normal metabolism,Initiate therapy with recommended starting dose,Strong,PA166161954
CYP2D6,Ondansetron,,,,Intermediate Metabolizer,Very limited data available for CYP2D6 intermediate metabolizers,Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose,No recommendation,PA166161954
CYP2D6,Ondansetron,,,,Poor Metabolizer,Very limited data available for CYP2D6 poor metabolizers,Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose,No recommendation,PA166161954
CYP2D6,Paroxetine,,,,Ultrarapid Metabolizer,Increased metabolism to less active compounds when compared to Normal Metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure,Select alternative drug not predominantly metabolized by CYP2D6,Strong,PA166127636
CYP2D6,Paroxetine,,,,Normal Metabolizer,Normal metabolism,Initiate therapy with recommended starting dose,Strong,PA166127636
CYP2D6,Paroxetine,,,,Intermediate Metabolizer,Reduced metabolism when compared to Normal Metabolizers. Higher plasma concentrations may increase the probability of side effects,Initiate therapy with recommended starting dose,Moderate,PA166127636
CYP2D6,Paroxetine,,,,Poor Metabolizer,Greatly reduced metabolism when compared to Normal Metabolizers. Higher plasma concentrations may increase the probability of side effects,"Select alternative drug not predominantly metabolized by CYP2D6 or if paroxetine use warranted, consider a 50% reduction of recommended starting dose and titrate to response",Optional,PA166127636
CYP2D6,Tamoxifen,,,,Ultrarapid Metabolizer,Therapeutic endoxifen concentrations,Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day),Strong,PA166176068
CYP2D6,Tamoxifen,,,,Normal Metabolizer,Therapeutic endoxifen concentrations,Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day),Strong,PA166176068
CYP2D6,Tamoxifen,,,1,Intermediate Metabolizer,"Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers","Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day). Avoid CYP2D6 strong to weak inhibitors",Optional,PA166176068
CYP2D6,Tamoxifen,*10,,1,Intermediate Metabolizer,"Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers","Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day). Avoid CYP2D6 strong to weak inhibitors",Moderate,PA166176068
CYP2D6,Tamoxifen,,,0.5,Intermediate Metabolizer,"Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers","Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day). Avoid CYP2D6 strong to weak inhibitors",Moderate,PA166176068
CYP2D6,Tamoxifen,,,,Poor Metabolizer,"Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers","Recommend alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype  and based on knowledge that CYP2D6 poor metabolizers switched from tamoxifen to anastrozole do not have an increased risk of recurrence. Note, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy",Strong,PA166176068
CYP2D6,Tramadol,,,,Ultrarapid Metabolizer,Increased formation of O-desmethyltramadol (active metabolite) leading to higher risk of toxicity.,"Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid",Strong,PA166228101
CYP2D6,Tramadol,,,,Normal Metabolizer,Expected O-desmethyltramadol (active metabolite) formation,Use tramadol label recommended age- or weight-specific dosing,Strong,PA166228101
CYP2D6,Tramadol,,,,Intermediate Metabolizer,Reduced O-desmethyltramadol (active metabolite) formation,"Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-codeine opioid",Optional,PA166228101
CYP2D6,Tramadol,,,,Poor Metabolizer,Greatly reduced O-desmethyltramadol (active metabolite) formation leading to diminished analgesia,"Avoid tramadol use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-codeine opioid",Strong,PA166228101
CYP2D6,Trimipramine,,,,Ultrarapid Metabolizer,Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure,"Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.
If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166105001
CYP2D6,Trimipramine,,,,Normal Metabolizer,Normal metabolism of TCAs,Initiate therapy with recommended starting dose,Strong,PA166105001
CYP2D6,Trimipramine,,,,Intermediate Metabolizer,Reduced metabolism of TCAs to less active compounds when compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects,Consider 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments,Optional,PA166105001
CYP2D6,Trimipramine,,,,Poor Metabolizer,Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects,"Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.
If a TCA is warranted, consider 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments",Optional,PA166105001
CYP2D6,Tropisetron,,,,Ultrarapid Metabolizer,Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting),Select and alternative drug not predominantly metabolized by CYP2D6 (i.e. granisetron),Moderate,PA166161955
CYP2D6,Tropisetron,,,,Normal Metabolizer,Normal metabolism,Initiate therapy with recommended starting dose,Strong,PA166161955
CYP2D6,Tropisetron,,,,Intermediate Metabolizer,Very limited data available for CYP2D6 intermediate metabolizers,Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose,No recommendation,PA166161955
CYP2D6,Tropisetron,,,,Poor Metabolizer,Very limited data available for CYP2D6 poor metabolizers,Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose,No recommendation,PA166161955
CYP3A5,Tacrolimus,,,,Normal Metabolizer,Lower dose-adjusted trough concentrations of tacrolimus and decreased chance of achieving target tacrolimus concentrations,Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments,Strong,PA166124619
CYP3A5,Tacrolimus,,,,Intermediate Metabolizer,Lower dose-adjusted trough concentrations of tacrolimus and decreased chance of achieving target tacrolimus concentrations,Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments,Strong,PA166124619
CYP3A5,Tacrolimus,,,,Poor Metabolizer,Higher (normal) dose-adjusted trough concentrations of tacrolimus and increased chance of achieving target tacrolimus concentrations,Initiate therapy with standard recommended dose. Use therapeutic drug monitoring to guide dose adjustments,Strong,PA166124619
HLA-A,Carbamazepine,*31:01,,,Normal or Reduced Risk,"Normal or reduced risk of carbamazepine-induced SJS/TEN, DRESS and MPE",Use carbamazepine per standard dosing guidelines,Strong,PA166105008
HLA-A,Carbamazepine,*31:01,,,Increased Risk,"Increased risk of carbamazepine-induced SJS/TEN, DRESS and MPE","If patient is carbamazepine-naive and alternative agents are available, do not use carbamazepine",Strong,PA166105008
HLA-B,Abacavir,*57:01,,,Normal or Reduced Risk,Low or reduced risk of abacavir hypersensitivity,Use abacavir per standard dosing guidelines,Strong,PA166104997
HLA-B,Abacavir,*57:01,,,Increased Risk,Significantly increased risk of abacavir hypersensitivity,Abacavir is not recommended,Strong,PA166104997
HLA-B,Allopurinol,*58:01,,,Normal or Reduced Risk,Low or reduced risk of allopurinol SCAR,Use allopurinol per standard dosing guidelines,Strong,PA166105003
HLA-B,Allopurinol,*58:01,,,Increased Risk,Significantly increased risk of allopurinol SCAR,Allopurinol is contraindicated,Strong,PA166105003
HLA-B,Carbamazepine,*15:02,,,Normal or Reduced Risk,"Normal or reduced risk of carbamazepine-induced SJS/TEN, DRESS and MPE.",Use carbamazepine per standard dosing guidelines.,Strong,PA166105008
HLA-B,Carbamazepine,*15:02,,,Increased Risk,Increased risk of carbamazepine-induced SJS/TEN,"If patient is carbamazepine-naive, do not use carbamazepine",Strong,PA166105008
HLA-B,"Fosphenytoin
Phenytoin",*15:02,,,Normal or Reduced Risk,Normal phenytoin metabolism,"No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to standard practice",Strong,PA166122806
HLA-B,"Fosphenytoin
Phenytoin",*15:02,,,Increased Risk,Increased risk of phenytoin-induced SJS/TEN,"If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.
Optional recommendation: If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing",Strong,PA166122806
HLA-B,Oxcarbazepine,*15:02,,,Normal or Reduced Risk,Normal or reduced risk of oxcarbazepine-induced SJS/TEN,Use oxcarbazepine per standard dosing guidelines.,Strong,PA166176623
HLA-B,Oxcarbazepine,*15:02,,,Increased Risk,Increased risk of oxcarbazepine-induced SJS/TEN,"If patient is oxcarbazepine-naive, do not use oxcarbazepine",Strong,PA166176623
IFNL3,"Peginterferon alfa-2a
Peginterferon alfa-2b
Ribavirin",,,,Favorable Response,"For PEG-IFN ALPHA and RBV based on the variation rs12979860
Approximately 70% chance for SVR after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens

For protease inhibitor combinations with PEG-IFN ALPHA and RBV based on the variation rs12979860
Approximately 90% chance for SVR after 24-48 weeks of treatment. Approximately 80-90% of patients are eligible for shortened therapy (24-28 weeks vs. 48 weeks). Weighs in favor of using PEG-IFN  alpha and RBV containing regimen",,Strong,PA166110235
IFNL3,"Peginterferon alfa-2a
Peginterferon alfa-2b
Ribavirin",,,,Unfavorable Response,"For PEG-IFN ALPHA and RBV based on the variation rs12979860
Approximately 30% chance for SVR after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens

For protease inhibitor combinations with PEG-IFN ALPHA and RBV based on the variation rs12979860
Approximately 60% chance for SVR after 24-48 weeks of treatment. Approximately 50% of patients are eligible for shortened therapy (24-28 weeks). Consider implications before initiating PEG-IFN  and RBV containing regimens.For PEG-IFN ALPHA and RBV: Approximately 70% chance for SVR c after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens",,Strong,PA166110235
RYR1,"Desflurane
Enflurane
Halothane
Isoflurane
Methoxyflurane
Sevoflurane
Succinylcholine",,,,Malignant Hyperthermia Susceptible,Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine,"Halogenated volatile anesthetics or depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS",Strong,PA166180457
RYR1,"Desflurane
Enflurane
Halothane
Isoflurane
Methoxyflurane
Sevoflurane
Succinylcholine",,,,Uncertain Susceptibility,"These results do not eliminate the chance that this patient is susceptible to Malignant Hyperthermia. The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants",Strong,PA166180457
CACNA1S,"Desflurane
Enflurane
Halothane
Isoflurane
Methoxyflurane
Sevoflurane
Succinylcholine",,,,Malignant Hyperthermia Susceptible,Individuals are at increased risk of developing malignant hyperthermia if administered halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine,"Halogenated volatile anesthetics or depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with MHS. They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS",Strong,PA166180457
CACNA1S,"Desflurane
Enflurane
Halothane
Isoflurane
Methoxyflurane
Sevoflurane
Succinylcholine",,,,Uncertain Susceptibility,"These results do not eliminate the chance that this patient is susceptible to Malignant Hyperthermia. The genetic cause of about half of all MH survivors, with MH susceptibility confirmed by contracture test, remains unknown","Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants",Strong,PA166180457
G6PD,Rasburicase,,,,Normal Metabolizer,Low or reduced risk of hemolytic anemia,No reason to withhold rasburicase based on G6PD status,Strong,PA166119846
G6PD,Rasburicase,,,,Deficient,At risk of acute hemolytic anemia,Rasburicase is contraindicated; alternatives include allopurinol,Strong,PA166119846
G6PD,Rasburicase,,,,Variable,Unknown risk of hemolytic anemia,"To ascertain that G6PD status is normal, enzyme activity must be measured; alternatives include allopurinol",Moderate,PA166119846
CFTR,Ivacaftor,,,,Ivacaftor responsive in CF patients,"Significant improvement in lung function, weight, risk of pulmonary exacerbation, patient reported outcomes, and reduction in sweat chloride concentrations through enhanced CFTR channel activity (increase probability of open channel)",Use ivacaftor according to the product label,Strong,PA166114461
CFTR,Ivacaftor,,,,Ivacaftor non-responsive in CF patients,Ivacaftor treatment is recommended only in cystic fibrosis (CF) patients that are either homozygous or heterozygous for certain CFTR variants.,Ivacaftor is not recommended,Moderate,PA166114461
CYP2C9,Warfarin,*2,,,Poor Function,,"Based on CYP2C9 *2, administer lower dosage through validated published pharmacogenomics algorithms","Non African Ancestry: Strong
African Ancestry: Moderate",PA166104949
CYP2C9,Warfarin,*3,,,Poor Function,,"Based on CYP2C9 *3, administer lower dosage through validated published pharmacogenomics algorithms","Non African Ancestry: Strong
African Ancestry: Moderate",PA166104949
CYP2C9,Warfarin,*5,,,Intermediate Metabolizer,,"Based on CYP2C9 5*, calculate dosage from validated pharmacogenetic algorithms","Non African Ancestry: Optional
African Ancestry: Moderate",PA166104949
CYP2C9,Warfarin,*6,,,Intermediate Metabolizer,,"Based on CYP2C9 *6, calculate dosage from validated pharmacogenetic algorithms","Non African Ancestry: Optional
African Ancestry: Moderate",PA166104949
CYP2C9,Warfarin,*8,,,Intermediate Metabolizer,,"Based on CYP2C9 *8, calculate dosage from validated pharmacogenetic algorithms","Non African Ancestry: Optional
African Ancestry: Moderate",PA166104949
CYP2C9,Warfarin,*11,,,Intermediate Metabolizer,,"Based on CYP2C9 *11, calculate dosage from validated pharmacogenetic algorithms","Non African Ancestry: Optional
African Ancestry: Moderate",PA166104949
CYP2C9,Warfarin,,,,Normal Metabolizer,,"Based on the variants present in CYP2C9, administer recommended dosage",,
RSID,Warfarin,,,,Poor Function,,"Based on rs12777823 carrier A, decrease calculated dosage by 10-25%",African Ancestry: Moderate,PA166104950
RSID,Warfarin,,,,Normal Metabolizer,,"Based on the absence of rs12777823, administer recommended dosage",,
RSID,Warfarin,,,,Unknown,,"Based on the rs12777823 carrier T, you have a genetic change that may alter how effective this medication is for you. However at this time we are not entirely sure what this change means or how/if this alters standard dosing recommendations. Changes to current medication(s) or dosing are not recommended based on this finding.",,
CYP4F2,Warfarin,,,,Increased Function,,"Based on rs2108622 carrier T in CYP4F2, increase dose by 5-10%",Non African Ancestry: Optional,PA166104949
CYP4F2,Warfarin,,,,Normal Metabolizer,,"Based on rs2108622 in CYP4F2, administer recommended dosage",,
VKORC1,Warfarin,,,,Poor Function,,"Based on VKORC1 1639G>A, administer lower dosage through validated published pharmacogenomics algorithms","Non African Ancestry: Strong
African Ancestry: Moderate",PA166104949
VKORC1,Warfarin,,,,Normal Metabolizer,,"Based on the absence of VKORC1 1639G>A, administer recommended dosage",,
